undamentalytics Newsletter
Sign in

ANI Pharmaceuticals Inc income statement

In fiscal 2025, ANI Pharmaceuticals Inc reported revenue of $883m, up 43.8% on the year before, operating income of $111m (a 12.6% margin) and net income of $78.3m, or $3.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue12020305676129177202207208216316487614883978
Cost of revenue———91011134979736387——————
Gross profit———112044648098129143121——————
Research and development144044123339152016112234455250
Selling, general and administrative———10161821283244566584124162250318325
General and administrative567———————————————
Operating income———−01203320283516−16−40−35471111150
Interest expense01110111111115139122936343331
Net interest income000———————————————
Income before tax—−46−52−201922916203−26−56−6320−2296143
Income tax———−00−965175−3−3−13−151−41734
Net income−48−46−52−2029154−1156−23−43−4819−1978108
Diluted EPS−$4.20−$4.21−$3.15−$1.27−$0.92$2.59$1.32$0.34−$0.09$1.30$0.50−$1.88−$3.40−$3.05$0.85−$1.04$3.32$4.92
Diluted shares (average)11m11m16m22m—11m12m12m12m12m12m12m13m16m18m19m21m22m
EBITDA———122440425669612972210768203236

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANIP vs HRMYANIP vs PBHANIP vs AXSMANIP vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from ANI Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ANI Pharmaceuticals Inc.